• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Generic drugs slow spending growth

Report: Generic drugs slow spending growth

March 13, 2014
CenterWatch Staff

Last year, $29.3 billion was spent on prescription drugs in Canada, but the annual growth rate was the second-lowest in more than 20 years, according to a new report by the Canadian Institute for Health Information(CIHI).

This slower growth in spending—2.3% in 2013—was due to increased use of less-expensive generic drugs and related pricing policies, reveals Prescribed Drug Spending in Canada, 2012: A Focus on Public Drug Programs. In total, prescription drugs accounted for 85% of the $34.5 billion that was spent on all drugs last year.

The report found generic drugs account for the majority of use but less than half of spending in public drug programs. In 2012, they made up 72.4% of claims but only 38.8% of spending.

The majority of public drug spending is for a small number of high-cost individuals. More than 60% of public drug money is used for 12% of Canadians, each of whom has more than $2,500 worth of prescription drugs paid for by public programs.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing